胞红蛋白在调控细胞铁死亡中的作用

近年来,以细胞内氧化还原平衡失调为重要诱因,具有铁依赖性和以脂质过氧化物堆积引起细胞膜损伤为主要特征的细胞铁死亡备受关注。越来越多的研究表明,细胞铁死亡在疾病发生及防治方面具有重要作用。胞红蛋白(cytoglobin,CYGB),又名星状细胞激活蛋白 (stellate cell activating protein, STAP),是一种珠蛋白,不仅能可逆地结合氧分子,储存和传递氧气,同时在其氨基酸序列中含2个半胱氨酸残基,可形成分子内部的二硫键,在感受细胞内氧化还原状态变动时,改变自身空间结构,引起生物活性及下游信号通路的变化。同时,CYGB还具有一氧化氮双加氧酶活性,能够清除过量一氧化氮与活性氧物质超氧阴离子反应生成的有毒ONOO^-,防止其对线粒体功能的破坏。而细胞内活氧物质和线粒体是影响细胞铁死亡的重要因素。因此,本综述主要围绕CYGB清除活性氧物质及调控一氧化氮代谢等的作用机制,并结合我们最近有关CYGB通过p53-YAP1轴调控细胞内脂质代谢的研究进行阐述,提出CYGB通过参与细胞铁死亡调控来行使功能,为心血管功能,肝纤维化及癌症发生等相关疾病的预防和治疗提供重要的理论依据。     

胞红蛋白研究进展

胞红蛋白(Cytoglobin,CYGB)是珠蛋白家族中的一员,在脊椎动物的器官,组织和细胞中有广泛表达。它具有一个紧密的双螺旋结构,不仅具有储存和运输氧气的功能,还参与胶原合成、酶促反应、清除细胞内活性氧、基因调控等过程。此外,胞红蛋白在体外能抑制癌细胞的生长,从而引起研究人员的高度关注。本文重点对CYGB的结构、分布、基因调控和功能、参与病理状态以及潜在的临床应用价值等方面展开综述。     

胞红蛋白酵母双杂交载体的构建与表达

胞红蛋白（CGB）是一种新发现的分布于胞浆与胞核的携氧珠蛋白。为探讨CGB在体内的相互作用蛋白,从而促进对其分子调控网络的认识,根据CGB基因的开放阅读框架设计并合成PCR引物,从人胎肝cDNA文库中扩增得到该基因编码区.测序分析正确后将其定向克隆到酵母表达载体pGBKT7中,构建获得CGB的酵母表达载体pGBKT7-CGB,并在酵母菌AH109中表达。提取酵母总蛋白并利用标签蛋白（myc）的抗体进行免疫印迹检测。结果表明所构建的CGB酵母表达载体能够在酵母中高效表达,可用于后续的酵母双杂交文库的筛选工作。     

胞红蛋白:一种新的携氧珠蛋白

胞红蛋白(CGB)是新发现的第四种携氧珠蛋白,广泛分布于多种组织和器官。在不同种类细胞中其亚细胞定位并不相同,在结缔组织中主要定位于细胞质,而在神经组织胞核和胞质中均有分布。小鼠和人CGB基因均编码190个氨基酸,斑马鱼的CGB基因编码174个氨基酸。人CGB基因定位于染色体17q25。系统进化分析表明,CGB与脊椎动物的肌红蛋白(MGB)有共同祖先。CGB可促进向细胞内运输氧,同时也可能作为一种NADH氧化酶或氧感受器而起作用。CGB的发现及其功能的深入研究,将使机体氧运输、氧代谢和氧利用的研究揭开全新的篇章。     

BMP-7在抑制肾脏纤维化中的作用

肾脏纤维化过程十分复杂,受到多种因素的作用,但总体上可以归结为两方面,一方面是促进纤维化的因素,为正调节因素;另一方面是抗纤维化的因素,为负调节因素。近年来,发现了一些肾脏纤维化的内源性负调节因素,比较公认的有肝细胞生长因子、骨形态发生蛋白、核心蛋白聚糖和过氧化物酶体增殖物激活受体等。该文介绍骨形态发生蛋白-7（BMP-7）在抑制肾脏纤维化方面的研究进展。     

脊椎动物球蛋白家族新成员--胞红蛋白

胞红蛋白(Cygb)是广泛存在于脊椎动物各类组织细胞中的球蛋白家族成员。Cygb为六配位体血红素单体蛋白质,能可逆结合O2、CO等气体配体,参与细胞内某些需氧酶反应。     

胞红蛋白在缺氧下的表达

胞红蛋白(cytoglobin,CYGB)是新发现的第4种携氧球蛋白,具有典型的"three-over-three"-螺旋三明治折叠结构.CYGB体内分布广泛,主要以单倍体形式存在于成纤维细胞及神经元细胞中.CYGB在缺氧下表达明显增强并具有保护组织细胞免遭缺血损伤的作用,其机制与其蛋白结构及基因表达有关.本文综述了胞红蛋白在缺氧下的表达以及内在机理.     

镍在浑球红假单胞菌氢酶合成中的作用（简报）

在固氮酶能表达的生长条件下,镍可促进浑球红假单胞菌菌株601的氢酶合成,而在含氨培养基上则没有影响。镍促进氢酶合成的最适浓度为10μmol/L,并具有金属专一性,其他二价金属离子对氢酶合成没有作用。镍在促进氢酶吸氢的同时,抑制菌体的放氢,但对固氮酶的乙炔还原活性则几乎没有影响。     

HE4荧光素酶报告基因载体构建与鉴定及其在肾脏纤维化中的作用

目的:通过构建HE4荧光素酶报告基因载体以及质粒转染以分析HIF-1α对HE4靶向调控,明确HE4调控肾脏纤维化的分子机制。方法:采用巢式PCR扩增HE4启动子片段,纯化酶切后定向克隆进p GL-3basic报告基因载体,进而与PRL-TK质粒共转染HK2细胞,检测荧光素酶的表达HIF-1α过表达质粒转染HK2细胞,western blot检测HE4分子的表达。HK2细胞转染HE4过表达质粒后检测COL4A1、COL1A1分子的表达。结果:获得HE4启动子荧光素酶报告载体,酶切鉴定结果与初期预测一致,荧光素酶检测结果证实HIF-1α可结合于HE4启动子上,从而启动HE4的表达。HK2细胞转染HIF-1α正义过表达质粒,HE4的m RNA和蛋白水平均显著增加。HK2细胞转染HE4过表达质粒,COL4A1、COL1A1表达水平上调。结论:本研究成功构建HE4启动子荧光素酶报告基因载体,证实HIF-1α为HE4上游靶基因,过表达的HE4可能通过上调COL4A1、COL1A1促进细胞外基质沉积促进肾脏纤维化的发生发展。     

外泌体在肝纤维化中的作用

外泌体(exosomes)是一种能被大多数细胞分泌的微小膜泡,是具有脂质双层膜结构的细胞外囊泡。现认为外泌体是细胞外囊泡(extracellular vesicles, EVs)的一种亚群。研究表明,外泌体是细胞间信息传递的一种载体。肝脏既可以分泌外泌体,同时也是其他组织细胞产生的外泌体的作用靶点,且肝内与肝外来源的外泌体与肝纤维化的形成、发生、发展均有密切联系。本文主要就外泌体在肝纤维化相关疾病中的作用及外泌体与肝纤维化指标之间的关系进行综述。     

莪术醇对非酒精性脂肪性肝大鼠肝功能和肝纤维化的影响及机制*

目的:探讨莪术醇(CC)对非酒精性脂肪性肝(NAFLD)大鼠模型肝功能和肝纤维化的影响及机制。方法:采用高脂饮食构建非酒精脂肪肝炎(NASH)伴肝纤维化的大鼠模型,将60只SD大鼠随机分为:空白对照组、模型组(NASH)、NASH+复方鳖甲软肝片(CBT)组(阳性对照组)、NASH+CC组(25、50、100 mg/kg),每组10只。测量大鼠肝脏占体重的百分比,测量大鼠高密度脂蛋白(HDL)、甘油三酯(TG)、谷丙转氨酶(ALT)、谷草转氨酶(AST)水平,HE染色观察肝纤维化情况,免疫组化检测鼠肝组织α-平滑肌肌动蛋白(α-SMA)表达及肝组织核因子κB p65(NF-κB p65)的阳性染色情况,蛋白印迹(Western blot)检测α-SMA、基质金属蛋白酶-1(MMP-1)、基质金属蛋白酶抑制剂-1(TIMP-1)蛋白表达及Toll样受体-4(TLR4)、转化生长因子激活激酶-1(TAK1)、NF-κB p65、血管细胞粘附分子-1(VCAM-1)蛋白的表达情况,酶联免疫吸附法(ELISA)检测肝组织中白介素(IL-6、IL-10、IL-1β)、肿瘤坏死因子-α(TNF-α)的表达。结果:与空白对照组相比,模型组大鼠HDL、 IL-10含量、MMP-1蛋白表达量显著降低(P＜0.05),TG、ALT、AST、肝组织P65阳性率,α-SMA、TIMP-1、TLR4、TAK1、NF-κB p65、VCAM-1表达、IL-6、TNF-α及IL-1β含量显著升高(P＜0.05)。与模型组相比,CBT和CC处理后大鼠HDL、 IL-10含量、MMP-1蛋白表达量显著升高(P＜0.05),TG、ALT、AST、肝组织P65阳性率,α-SMA、TIMP-1、TLR4、TAK1、NF-κB p65、VCAM-1表达、IL-6、TNF-α及IL-1β含量显著降低(P＜0.05),其中模型+CC组以高浓度组改善最显著(P＜0.05),但各剂量改善幅度均低于模型+CBT组(P＜0.05)。结论:莪术醇通过调节TLR4、TAK1、NF-κB p65信号通路,减轻炎症反应,改善肝功能,从而缓解非酒精性脂肪肝肝肝纤维化,且在一定范围内呈浓度依赖性。     

Bone-marrow-derived cells cultured in serum-free medium reduce liver fibrosis and improve liver function in carbon-tetrachloride-treated cirrhotic mice

We have previously developed autologous bone marrow cell infusion (ABMi) therapy for liver cirrhosis patients. One problem associated with ABMi therapy is that general anesthesia is required to obtain 400 ml bone marrow fluid from liver cirrhosis patients. However, many patients with decompensated cirrhosis do not meet the criteria, because of decreased liver function or an increased bleeding tendency. To overcome these issues, our aim is to derive liver repair cells from small amounts of autologous bone marrow aspirates obtained under local anesthesia and to use these cells in liver cirrhosis patients. Here, we conducted, by using a mouse model, basic research aimed at achieving novel liver regeneration therapy. We cultured bone marrow cells aspirated from the femurs of C57 BL/6 Tg14 (act-EGFP) OsbY01 mice (green fluoresent protein [GFP]-transgenic mice). After 14 days of culture with serum-free medium (good manufacturing practice grade), the obtained spindle-shaped GFP-positive cells were injected (1×10⁴ cells) via the caudal vein into mice with carbon tetrachloride (CCl₄)-induced cirrhosis. Numerous cultured macrophages and some mesenchymal stem cells repopulated the cirrhotic liver. The results showed that serum albumin, liver fibrosis and liver function were significantly improved in the group treated with cultured bone marrow cells (P<0.01). Moreover, matrix metalloproteinase-9 expression was increased in the liver (P<0.01). Thus, infusion of bone-marrow-derived cultured cells improved liver function and liver fibrosis in mice with CCl₄-induced cirrhosis.     

Molecular pathways involved in loss of kidney graft function with tubular atrophy and interstitial fibrosis

Loss of kidney graft function with tubular atrophy (TA) and interstitial fibrosis (IF) causes most kidney allograft losses. We aimed to identify the molecular pathways involved in IF/TA progression. Kidney biopsies from normal kidneys (n = 24), normal allografts (n = 6), and allografts with IF/TA (n = 17) were analyzed using high-density oligonucleotide microarray. Probe set level tests of hypotheses tests were conducted to identify genes with a significant trend in gene expression across the three groups using Jonckheere-Terpstra test for trend. Interaction networks and functional analysis were used. An unsupervised hierarchical clustering analysis showed that all the IF/TA samples were associated with high correlation. Gene ontology classified the differentially expressed genes as related to immune response, inflammation, and matrix deposition. Chemokines (CX), CX receptor (for example, CCL5 and CXCR4), interleukin, and interleukin receptor (for example, IL-8 and IL10RA) genes were overexpressed in IF/TA samples compared with normal allografts and normal kidneys. Genes involved in apoptosis (for example, CASP4 and CASP5) were importantly overexpressed in IF/TA. Genes related to angiogenesis (for example, ANGPTL3, ANGPT2, and VEGF) were downregulated in IF/TA. Genes related to matrix production-deposition were upregulated in IF/TA. A distinctive gene expression pattern was observed in IF/TA samples compared with normal allografts and normal kidneys. We were able to establish a trend in gene expression for genes involved in different pathways among the studied groups. The top-scored networks were related to immune response, inflammation, and cell-to-cell interaction, showing the importance of chronic inflammation in progressive graft deterioration.     

聚乙二醇修饰重组细胞珠蛋白对小鼠急性肝损伤的保护作用

旨在探究聚乙二醇修饰重组细胞珠蛋白(PEG modified recombinant cytoglobin,PEG-rCygb)对小鼠急性肝损伤的保护作用。采用CCl4诱导KM小鼠急性肝损伤模型,尾静脉注射PEG-rCygb,收集血清及肝脏组织检测各项生化指标及组织病理学变化。结果表明,PEG-rCygb治疗组小鼠肝脏系数减小,血清中AST﹑ALT水平降低,肝组织匀浆中MDA含量减少,GSH含量增加,T-SOD、CAT活性升高。肝组织切片HE染色显示PEG-rCygb可以缓解肝细胞脂肪变性,减少炎症因子,减轻肝细胞损伤。体外细胞学实验表明rCygb经PEG修饰后对H2O2造成的肝星状细胞(HSC)氧化损伤发挥的保护作用增强。研究结果显示PEG-rCygb提高了机体对自由基的清除能力,对CCl4引起的小鼠急性肝损伤具有保护作用。     

The PDGF system and its antagonists in liver fibrosis

Platelet derived growth factor (PDGF) signaling plays an important role in activated hepatic stellate cells and portal fibroblast proliferation, chemotaxis, migration and cell survival. PDGF receptors and ligands are upregulated in experimental liver fibrotic models as well as in human liver fibrotic diseases. Blocking of PDGF signaling ameliorates experimental liver fibrogenesis. The plurality of molecular and cellular activities of PDGF and its involvement in initiation, progression and resolution of hepatic fibrogenesis offers an infinite number of therapeutic possibilities. These include the application of therapeutic antibodies (e.g. AbyD3263, MOR8457) which specifically sequester individual PDGF isoforms or the inhibition of PDGF isoforms by synthetic aptamers. In particular, the isolation of innovative slow off-rate modified aptamers (e.g., SOMAmer SL1 and SL5) that carry functional groups absent in natural nucleic acids by the Systematic Evolution of Ligands by EXponential (SELEX) enrichment technique offers the possibility to design high affinity aptamers that target PDGF isoforms for clinical purposes. Dominant-negative soluble PDGF receptors are also effective in attenuation of hepatic stellate cell proliferation and hepatic fibrogenesis. Moreover, some multikinase inhibitors targeting PDGF signaling have been intensively tested during the last decade and are on the way into advanced preclinical studies and clinical trials. This narrative review aims to gauge the recent progression of research into PDGF systems and liver fibrosis.     

Endoglin in liver fibrosis

Liver fibrosis occurs in most types of chronic liver diseases and is characterized by excessive accumulation of extracellular matrix proteins, leading to disruption of tissue function and eventually organ failure. Transforming growth factor (TGF)-β represents an important pro-fibrogenic factor and aberrant TGF-β action has been implicated in many disease processes of the liver. Endoglin is a TGF-β co-receptor expressed mainly in endothelial cells that has been shown to differentially regulates TGF-β signal transduction by inhibiting ALK5-Smad2/3 signalling and augmenting ALK1-Smad1/5 signalling. Recent reports demonstrating upregulation of endoglin expression in pro-fibrogenic cell types such as scleroderma fibroblasts and hepatic stellate cells have led to studies exploring the potential involvement of this TGF-β co-receptor in organ fibrosis. A recent article by Meurer and colleagues now shows that endoglin expression is increased in transdifferentiating hepatic stellate cells in vitro and in two different models (carbon tetrachloride intoxication and bile duct ligation) of liver fibrosis in vivo. Moreover, they show that endoglin overexpression in hepatic stellate cells is associated with enhanced TGF-β-driven Smad1/5 phosphorylation and α-smooth muscle actin production without altering Smad2/3 signaling. These findings suggest that endoglin may play an important role in hepatic fibrosis by altering the balance of TGF-β signaling via the ALK1-Smad1/5 and ALK-Smad2/3 pathways and raise the possibility that targeting endoglin expression in transdifferentiating hepatic stellate cells may represent a novel therapeutic strategy for the treatment of liver fibrosis.     

NOX in liver fibrosis

NADPH oxidase is a multi-protein complex producing reactive oxygen species (ROS) both in phagocytic cells, being essential in host defense, and in non-phagocytic cells, regulating intracellular signalling. In the liver, NADPH oxidase plays a central role in fibrogenesis. A functionally active form of the NADPH oxidase is expressed not only in Kupffer cells (phagocytic cell type) but also in hepatic stellate cells (HSCs) (non-phagocytic cell type), suggesting a role of the non-phagocytic NADPH oxidase in HSC activation. Consistent with this concept, profibrogenic agonists such as Angiotensin II (Ang II) and platelet derived growth factor (PDGF), or apoptotic bodies exert their activity through NADPH oxidase-activation in HSCs. Both pharmacological inhibition with DPI and genetic studies using p47(phox) knockout mice provided evidence for a central role of NADPH oxidase in the regulation of HSC-activity and liver fibrosis. In addition to the p47(phox) component, only Rac1 has been identified as a functional active component of the NADPH oxidase complex in HSCs.     

肝纤维化的表观遗传学研究进展

肝纤维化是常见的慢性进行性肝病,是慢性肝病发展到肝硬化阶段的必经阶段,却有逆转的可能性。肝纤维化的中心环节是肝星状细胞的激活。关于肝星状细胞的激活,除了经典的肝纤维化通路,不断有新的通路和机制出现,包括自噬、内质网应激、氧化应激、胆固醇代谢和表观遗传,这些都揭示了肝星状细胞的活化机制。表观遗传包括DNA甲基化、组蛋白修饰和调节性非编码RNAs,这些机制也参与调节肝星状细胞活化和肝纤维化发生,对表观遗传和肝纤维化治疗之间的关系研究具有重要意义。